Crohn's Disease — The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease
Citation(s)
A Randomized, Double-blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease